182 related articles for article (PubMed ID: 35216581)
1. Effects of veverimer on serum bicarbonate and physical function in women with chronic kidney disease and metabolic acidosis: a subgroup analysis from a randomised, controlled trial.
Mathur VS; Wesson DE; Tangri N; Li E; Bushinsky DA
BMC Nephrol; 2022 Feb; 23(1):82. PubMed ID: 35216581
[TBL] [Abstract][Full Text] [Related]
2. Effects of veverimer on serum bicarbonate and physical function in diabetic patients with chronic kidney disease and metabolic acidosis: subgroup analysis from a randomized, controlled trial.
Mathur VS; Li E; Wesson DE
Nephrol Dial Transplant; 2022 Jun; 37(7):1302-1309. PubMed ID: 34240198
[TBL] [Abstract][Full Text] [Related]
3. Veverimer versus placebo in patients with metabolic acidosis associated with chronic kidney disease: a multicentre, randomised, double-blind, controlled, phase 3 trial.
Wesson DE; Mathur V; Tangri N; Stasiv Y; Parsell D; Li E; Klaerner G; Bushinsky DA
Lancet; 2019 Apr; 393(10179):1417-1427. PubMed ID: 30857647
[TBL] [Abstract][Full Text] [Related]
4. Long-term safety and efficacy of veverimer in patients with metabolic acidosis in chronic kidney disease: a multicentre, randomised, blinded, placebo-controlled, 40-week extension.
Wesson DE; Mathur V; Tangri N; Stasiv Y; Parsell D; Li E; Klaerner G; Bushinsky DA
Lancet; 2019 Aug; 394(10196):396-406. PubMed ID: 31248662
[TBL] [Abstract][Full Text] [Related]
5. VALOR-CKD: A Multicenter, Randomized, Double-Blind Placebo-Controlled Trial Evaluating Veverimer in Slowing Progression of CKD in Patients with Metabolic Acidosis.
Tangri N; Mathur VS; Bushinsky DA; Klaerner G; Li E; Parsell D; Stasiv Y; Walker M; Wesson DE; Wheeler DC; Perkovic V; Inker LA
J Am Soc Nephrol; 2024 Mar; 35(3):311-320. PubMed ID: 38261535
[TBL] [Abstract][Full Text] [Related]
6. Design and population of the VALOR-CKD study: a multicenter, randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of veverimer in slowing progression of chronic kidney disease in patients with metabolic acidosis.
Mathur VS; Bushinsky DA; Inker L; Klaerner G; Li E; Parsell D; Perkovic V; Stasiv Y; Walker M; Wesson DE; Wheeler DC; Tangri N
Nephrol Dial Transplant; 2023 May; 38(6):1448-1458. PubMed ID: 36331426
[TBL] [Abstract][Full Text] [Related]
7. Mechanism of Action of Veverimer: A Novel, Orally Administered, Nonabsorbed, Counterion-Free, Hydrochloric Acid Binder under Development for the Treatment of Metabolic Acidosis in Chronic Kidney Disease.
Klaerner G; Shao J; Biyani K; Kade M; Kierstead P; Gbur R; Tabakman S; Nguyen S; Buysse J
J Pharmacol Exp Ther; 2020 Dec; 375(3):439-450. PubMed ID: 33033169
[TBL] [Abstract][Full Text] [Related]
8. Randomized, Controlled Trial of TRC101 to Increase Serum Bicarbonate in Patients with CKD.
Bushinsky DA; Hostetter T; Klaerner G; Stasiv Y; Lockey C; McNulty S; Lee A; Parsell D; Mathur V; Li E; Buysse J; Alpern R
Clin J Am Soc Nephrol; 2018 Jan; 13(1):26-35. PubMed ID: 29102959
[TBL] [Abstract][Full Text] [Related]
9. Advances in management of chronic metabolic acidosis in chronic kidney disease.
Chen W; Abramowitz MK
Curr Opin Nephrol Hypertens; 2019 Sep; 28(5):409-416. PubMed ID: 31232712
[TBL] [Abstract][Full Text] [Related]
10. Clinical and cost-effectiveness of oral sodium bicarbonate therapy for older patients with chronic kidney disease and low-grade acidosis (BiCARB): a pragmatic randomised, double-blind, placebo-controlled trial.
BiCARB study group
BMC Med; 2020 Apr; 18(1):91. PubMed ID: 32268897
[TBL] [Abstract][Full Text] [Related]
11. Impact of Serum Bicarbonate Levels on Muscle Mass and Kidney Function in Pre-Dialysis Chronic Kidney Disease Patients.
Kittiskulnam P; Srijaruneruang S; Chulakadabba A; Thokanit NS; Praditpornsilpa K; Tungsanga K; Eiam-Ong S
Am J Nephrol; 2020; 51(1):24-34. PubMed ID: 31752000
[TBL] [Abstract][Full Text] [Related]
12. Does oral sodium bicarbonate therapy improve function and quality of life in older patients with chronic kidney disease and low-grade acidosis (the BiCARB trial)? Study protocol for a randomized controlled trial.
Witham MD; Band MM; Littleford RC; Avenell A; Soiza RL; McMurdo ME; Sumukadas D; Ogston SA; Lamb EJ; Hampson G; McNamee P;
Trials; 2015 Aug; 16():326. PubMed ID: 26231610
[TBL] [Abstract][Full Text] [Related]
13. Correction of metabolic acidosis improves insulin resistance in chronic kidney disease.
Bellasi A; Di Micco L; Santoro D; Marzocco S; De Simone E; Cozzolino M; Di Lullo L; Guastaferro P; Di Iorio B;
BMC Nephrol; 2016 Oct; 17(1):158. PubMed ID: 27770799
[TBL] [Abstract][Full Text] [Related]
14. Sodium bicarbonate for kidney transplant recipients with metabolic acidosis in Switzerland: a multicentre, randomised, single-blind, placebo-controlled, phase 3 trial.
Mohebbi N; Ritter A; Wiegand A; Graf N; Dahdal S; Sidler D; Arampatzis S; Hadaya K; Mueller TF; Wagner CA; Wüthrich RP
Lancet; 2023 Feb; 401(10376):557-567. PubMed ID: 36708734
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of Veverimer in the Treatment of Metabolic Acidosis Caused by Chronic Kidney Disease: A Meta-analysis.
Liu W; Li L; Zhang X; Dong H; Lu M
Front Pharmacol; 2021; 12():643128. PubMed ID: 33995050
[TBL] [Abstract][Full Text] [Related]
16. Veverimer: An Emerging Potential Treatment Option for Managing the Metabolic Acidosis of CKD.
Adrogué HJ; Madias NE
Am J Kidney Dis; 2020 Dec; 76(6):861-867. PubMed ID: 32920151
[TBL] [Abstract][Full Text] [Related]
17. Assessment of the Potential for Veverimer Drug-Drug Interactions.
Parsell D; Shao J; Guttendorf R; Mathur V; Li E; Wu YS; Tsao L; Tabakman S; Stasiv Y; Lee A; Biyani K; Klaerner G
Drug Metab Dispos; 2021 Jul; 49(7):490-500. PubMed ID: 34031138
[TBL] [Abstract][Full Text] [Related]
18. Effects of Sodium Bicarbonate in CKD Stages 3 and 4: A Randomized, Placebo-Controlled, Multicenter Clinical Trial.
Melamed ML; Horwitz EJ; Dobre MA; Abramowitz MK; Zhang L; Lo Y; Mitch WE; Hostetter TH
Am J Kidney Dis; 2020 Feb; 75(2):225-234. PubMed ID: 31699517
[TBL] [Abstract][Full Text] [Related]
19. Metabolic acidosis is common and associates with disease progression in children with chronic kidney disease.
Harambat J; Kunzmann K; Azukaitis K; Bayazit AK; Canpolat N; Doyon A; Duzova A; Niemirska A; Sözeri B; Thurn-Valsassina D; Anarat A; Bessenay L; Candan C; Peco-Antic A; Yilmaz A; Tschumi S; Testa S; Jankauskiene A; Erdogan H; Rosales A; Alpay H; Lugani F; Arbeiter K; Mencarelli F; Kiyak A; Dönmez O; Drozdz D; Melk A; Querfeld U; Schaefer F;
Kidney Int; 2017 Dec; 92(6):1507-1514. PubMed ID: 28729033
[TBL] [Abstract][Full Text] [Related]
20. Chronic Metabolic Acidosis in Chronic Kidney Disease.
Patschan D; Patschan S; Ritter O
Kidney Blood Press Res; 2020; 45(6):812-822. PubMed ID: 33264780
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
